Tenofovir Disoproxil Fumarate Reduce Incidence of HCC Development in CHB-patients with Compensated Cirrhosis

Overview

Journal Infect Agent Cancer

Publisher Biomed Central

Specialty Infectious Diseases

Date 2018 Sep 6

PMID 30181772

Citations 3

Authors

Ping Zhang

Qingli Liu

Mei Yuan

Lina Wang

Affiliations

Soon will be listed here.

Abstract

Background: The impact of different anti-virus regimens on prognosis of Chronic hepatitis B (CHB) related cirrhosis remains to be explored. We aim to investigate whether CHB-related HCC patients receiving nucleoside analogue regimen or not have a different prognosis.

Methods: Two hundred forty-two CHB-related compensated cirrhosis patients were attributed into groups regarding their anti-virus regimens containing tenofovir disoproxil fumarate (TDF) or not. The results of two groups were reviewed and investigated. The probability of hepatocellular carcinoma (HCC) development among each group were analyzed and compared.

Results: Two hundred forty-two CHB-related compensated cirrhosis patients from 2008 June to 2011 December were included in our study. One hundred twenty-seven patients received anti-virus regimen containing TDF and 115 patients received anti-virus regimen without TDF. Child-Pugh score, alanine aminotransferase (ALT), total bilirubin level, status of hepatitis B e antigen (HBeAg) and serum HBV DNA level were compared between groups. The cumulative probability of HCC development in TDF-contained group were significantly lower than it in non-TDF-contained group ( < 0.05). Multi-variant analysis indicated that TDF-containing regimen treatment was significantly associated with lower probability of HCC development, (hazard ratio, 0.18; 95% confidence interval range, 0.07-0.45, < 0.05).

Conclusion: Anti-virus regimen containing TDF benefits for the prognosis of CHB-related liver cirrhosis patients.

Citing Articles

Long-term effect of chronic hepatitis B on mortality in HIV-infected persons in a differential HBV transmission setting.

Umutesi J, Nsanzimana S, Yingkai Liu C, Vanella P, Ott J, Krause G BMC Infect Dis. 2022; 22(1):500.

PMID: 35624437 PMC: 9137150. DOI: 10.1186/s12879-022-07477-1.

Serum Zonulin in HBV-Associated Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma.

Wang X, Li M, Niu Y, Zhang X, Yin J, Zhao C Dis Markers. 2019; 2019:5945721.

PMID: 31485278 PMC: 6710742. DOI: 10.1155/2019/5945721.

Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis.

Lee J, Lee H, Kim S, Ahn S, Lee K Cancers (Basel). 2019; 11(3).

PMID: 30934621 PMC: 6468874. DOI: 10.3390/cancers11030425.

References

Sia D, Villanueva A, Friedman S, Llovet J . Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017; 152(4):745-761. DOI: 10.1053/j.gastro.2016.11.048. View

Hann H, Coben R, Brown D, Needleman L, Rosato E, Min A . A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Med. 2014; 3(2):390-6. PMC: 3987088. DOI: 10.1002/cam4.197. View

Singal A, El-Serag H . Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015; 13(12):2140-51. PMC: 4618036. DOI: 10.1016/j.cgh.2015.08.014. View

Ding J, Wang H . Multiple interactive factors in hepatocarcinogenesis. Cancer Lett. 2013; 346(1):17-23. DOI: 10.1016/j.canlet.2013.12.024. View

Wang J, Kao F, Wu C, Hung Y, Chao Y, Chou Y . Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study. Cancer. 2014; 121(9):1446-55. DOI: 10.1002/cncr.29159. View

Parikh P, Ryan J, Tsochatzis E . Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017; 5(3):40. PMC: 5326648. DOI: 10.21037/atm.2017.01.28. View

Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao Y . Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011; 21(6):401-16. PMC: 3899457. DOI: 10.2188/jea.je20100190. View

Ma K, Cheung T . Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. J Hepatocell Carcinoma. 2017; 4:1-9. PMC: 5207474. DOI: 10.2147/JHC.S96085. View

Iloeje U, Yang H, Jen C, Su J, Wang L, You S . Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007; 5(8):921-31. DOI: 10.1016/j.cgh.2007.06.015. View

10.

Wei K, Yu X, Zheng R, Peng X, Zhang S, Ji M . Incidence and mortality of liver cancer in China, 2010. Chin J Cancer. 2014; 33(8):388-94. PMC: 4135368. DOI: 10.5732/cjc.014.10088. View

11.

Stroffolini T, Sagnelli E, Rapicetta M, Felaco F, Filippini P, Annella T . Hepatitis B virus DNA in chronic HBsAg carriers: correlation with HBeAg/anti-HBe status, anti-HD and liver histology. Hepatogastroenterology. 1992; 39(1):62-5. View

12.

Ott J, Stevens G, Groeger J, Wiersma S . Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12):2212-9. DOI: 10.1016/j.vaccine.2011.12.116. View

13.

Chan A, Chok K, Yuen W, Chan S, Poon R, Lo C . Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg. 2011; 146(6):675-81. DOI: 10.1001/archsurg.2011.125. View

14.

Tawada A, Kanda T, Imazeki F, Yokosuka O . Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int. 2016; 10(4):574-93. DOI: 10.1007/s12072-016-9720-y. View

15.

Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H . Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2012; 58(1):98-107. DOI: 10.1002/hep.26180. View

16.

Hiraoka A, Kawamura T, Aibiki T, Okudaira T, Toshimori A, Yamago H . Prognosis and therapy for ruptured hepatocellular carcinoma: problems with staging and treatment strategy. Eur J Radiol. 2015; 84(3):366-371. DOI: 10.1016/j.ejrad.2014.11.038. View

17.

Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8):646-9. DOI: 10.1002/bjs.1800600817. View

18.

Romeo R, Petruzziello A, Pecheur E, Facchetti F, Perbellini R, Galmozzi E . Hepatitis delta virus and hepatocellular carcinoma: an update. Epidemiol Infect. 2018; 146(13):1612-1618. PMC: 9507952. DOI: 10.1017/S0950268818001942. View

19.

Wu J, Huang Y, Chau G, Su C, Lai C, Lee P . Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009; 51(5):890-7. DOI: 10.1016/j.jhep.2009.07.009. View

20.

Wu C, Lin J, Ho H, Su C, Lee T, Wang S . Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014; 147(1):143-151.e5. DOI: 10.1053/j.gastro.2014.03.048. View